Stocks · News reference

Revolution Medicines Says FDA Granted Breakthrough Therapy Designation To RASONQUE In Combination With Gemcitabine And Nab-Paclitaxel For Treatment-Naive Metastatic Pancreatic Adenocarcinoma

Sep 14, 2026, 8:10 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 10, 2026, 12:09 PMBenzinga Newsdesk
Morgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255
Morgan Stanley analyst Sean Laaman initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Overweight rating and announces Price Target of $255.
RVMD
BenzingaSep 9, 2026, 3:01 PMBenzinga Newsdesk
Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230
RVMD
BenzingaSep 3, 2026, 7:49 AMBenzinga Newsdesk
Reported Earlier, Revolution Medicines Lung Cancer Drug Shows 42% Response Rate In Early Trial
Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that
RVMD